SPLENIC MARGINAL ZONE LYMPHOMA
Clinical trials for SPLENIC MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SPLENIC MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for SPLENIC MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to control rare spleen cancer
Disease control OngoingThis study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare, slow-growing lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE3 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated May 26, 2026 06:51 UTC
-
New drug combo shows promise for rare lymphoma in phase II trial
Disease control OngoingThis phase II trial is testing a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (MZL), a type of blood cancer. The study aims to see how well the treatment controls the disease and how safe it is. About 175 participants with dif…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated May 26, 2026 06:49 UTC
-
Smarter CMV strategy may protect stem cell transplant patients
Disease control OngoingThis study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 06:45 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New hope for relapsed lymphoma: drug cocktail targets cancer cells
Disease control OngoingThis early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated May 15, 2026 11:53 UTC